Log in to your Inderes Free account to see all free content on this page.
AstraZeneca
1,783.50 SEK
-2.27 %
Less than 1K followers
AZN
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for AstraZeneca
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 220,379.6 | 218,476.3 | 338,779.5 | 462,833.7 | 462,187.2 | 596,387.3 | 540,239.6 |
| growth-% | -0.9 % | 55.1 % | 36.6 % | -0.1 % | 29.0 % | -9.4 % | |
| EBITDA | 62,527.4 | 68,217.9 | 68,684.9 | 96,394.6 | 137,008.6 | 184,090.0 | 179,126.4 |
| EBIT | 27,345.2 | 42,370.5 | 9,561.2 | 39,206.9 | 82,659.2 | 110,326.1 | 126,398.4 |
| Profit before taxes | 14,476.9 | 32,143.1 | -2,399.4 | 26,099.7 | 69,604.0 | 95,855.6 | 114,064.8 |
| Net income | 11,474.9 | 25,806.4 | 1,041.2 | 34,364.8 | 60,140.5 | 77,657.3 | 94,115.9 |
| EPS | 9.60 | 19.99 | 0.68 | 22.12 | 38.74 | 50.07 | 60.70 |
| Dividend | 26.19 | 15.33 | 25.99 | 30.26 | 29.26 | 34.19 | 29.43 |
| Dividend ratio | 272.9 % | 76.7 % | 3,831.8 % | 136.8 % | 75.5 % | 68.3 % | 48.5 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 28.4 % | 31.2 % | 20.3 % | 20.8 % | 29.6 % | 30.9 % | 33.2 % |
| EBIT-% | 12.4 % | 19.4 % | 2.8 % | 8.5 % | 17.9 % | 18.5 % | 23.4 % |
| ROE | 8.4 % | 20.1 % | 0.3 % | 8.9 % | 15.2 % | 17.2 % | 21.0 % |
| ROI | 2.0 % | 4.7 % | 0.1 % | 3.4 % | 5.9 % | 6.8 % | 9.0 % |
Login required
This content is only available for logged in users